Gain Therapeutics Announces Oral Presentation at 3rd International GBA1 Meeting 2026
Rhea-AI Summary
Gain Therapeutics (NASDAQ: GANX) will deliver an oral presentation at the 3rd International GBA1 Meeting 2026 on May 22, 2026 in Phoenix, AZ. The talk is titled “An update on the development of the GCase modulator GT-02287 for Parkinson’s disease”.
Jonas Hannestad, M.D., Ph.D., Chief Medical Officer, is listed as the presenter for a 15-minute session on May 22 at 4:15–4:30pm MST. Management will also attend the 7th World Parkinson’s Congress, May 24–27, 2026 in Phoenix.
Positive
- None.
Negative
- None.
News Market Reaction – GANX
In the Apr 24 session, GANX gained 4.23%, reflecting a moderate positive market reaction. Argus tracked a peak move of +4.1% during that session. Our momentum scanner triggered 7 alerts that day, indicating moderate trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Mar 26 | Earnings & update | Negative | -3.6% | 2025 results with net loss and clinical update for GT-02287. |
| Mar 19 | Conference appearance | Positive | +2.6% | CEO fireside chat and meetings at 38th ROTH Conference. |
| Mar 18 | Clinical data update | Positive | -25.6% | Phase 1b and preclinical data for GT-02287 and GT-04686 at AD/PD. |
| Mar 12 | Conference & FDA update | Positive | -3.2% | AD/PD 2026 presentations and U.S. FDA regulatory timing update. |
| Feb 19 | Conference appearance | Positive | +3.3% | Management presentation at Oppenheimer healthcare conference. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent history shows mixed reactions: conference and corporate events often align with price moves, while positive clinical data have previously seen sharp selloffs, indicating a tendency for good news to be faded.
Over recent months, Gain has focused on advancing GT-02287 through Phase 1b and preparing for Phase 2, alongside multiple conference appearances and its 2025 year-end report. Clinical updates at AD/PD 2026 and prior Phase 1b data were followed by notable price declines, while conference participation headlines (ROTH, Oppenheimer) coincided with modest gains. Today’s meeting-focused news fits the pattern of frequent visibility events around GT-02287 as regulatory and clinical milestones approach.
Key Terms
gba1 medical
gcase medical
parkinson’s disease medical
preclinical studies medical
clinical trials medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
BETHESDA, Md., April 24, 2026 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced an oral presentation at the 3rd International GBA1 Meeting 2026, being held May 22-23, 2026, in Phoenix, AZ.
| Details of the oral presentation are as follows: | |
| Presentation Title: | “An update on the development of the GCase modulator GT-02287 for Parkinson’s disease” |
| Presenter: | Jonas Hannestad, M.D., Ph.D., Chief Medical Officer of Gain |
| Session Name: | In the pipeline: updates from pharma on ongoing preclinical studies and clinical trials |
| Date: | May 22, 2026 |
| Time: | 4:15-4:30pm MST |
Management will also attend the 7th World Parkinson’s Congress, being held May 24-27, 2026, in Phoenix, AZ.
About GT-02287
Gain Therapeutics’ lead drug candidate, GT-02287, is in clinical development for the treatment of Parkinson’s disease (PD) with or without a GBA1 mutation. The orally administered, brain-penetrant small molecule is an allosteric enzyme modulator that restores the function of the lysosomal enzyme glucocerebrosidase (GCase) which becomes misfolded and impaired due to mutations in the GBA1 gene, the most common genetic abnormality associated with PD, or other age-related stress factors.
In preclinical models of PD, GT-02287 restored GCase enzymatic function, reduced ER stress, lysosomal and mitochondrial pathology, aggregated α-synuclein, neuroinflammation and neuronal death, as well as plasma neurofilament light chain (NfL) levels, a biomarker of neurodegeneration. In rodent models of both GBA1-PD and idiopathic PD, GT-02287 was shown to rescue deficits in motor function and gait and prevent the development of deficits in complex behaviors such as nesting. Compelling data in these models, demonstrating a disease-modifying effect of GT-02287, suggest that the drug candidate may have the potential to slow or stop the progression of Parkinson’s disease.
Results from a Phase 1 study of GT-02287 in healthy volunteers demonstrated favorable safety and tolerability, plasma and CNS exposures in the projected therapeutic range, and target engagement with an increase in GCase activity among those receiving GT-02287 at clinically relevant doses.
GT-02287 is currently being evaluated in a Phase 1b clinical trial for the treatment of Parkinson’s disease with or without a GBA1 mutation. The primary endpoint of the trial, which enrolled participants across seven sites in Australia, is to evaluate the safety and tolerability of GT-02287 after three months of dosing in people with Parkinson’s disease. The recently commenced Phase 1b study extension allows participants to continue to be treated with GT-02287 for up to a total of 12 months.
Initial results from the Phase 1b clinical trial in people with Parkinson’s disease demonstrated central nervous system target engagement, a reduction to baseline levels in the prespecified endpoint glucosylsphingosine (GluSph), and improvement or stabilization in MDS-UPDRS scores.
Gain’s lead program in Parkinson’s disease has been awarded funding support early in its development from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) and The Silverstein Foundation for Parkinson’s with GBA, as well as from the Eurostars-2 joint program with co-funding from the European Union Horizon 2020 research and Innosuisse – Swiss Innovation Agency.
About Gain Therapeutics, Inc.
Gain Therapeutics, Inc. is a clinical-stage biotechnology company leading the discovery and development of next generation allosteric therapies. Gain’s lead drug candidate, GT-02287 is currently being evaluated for the treatment of Parkinson’s disease with or without a GBA1 mutation in a Phase 1b clinical trial. GT-02287 has further potential in Gaucher’s disease, dementia with Lewy bodies, and Alzheimer’s disease. Gain has multiple undisclosed preclinical assets targeting lysosomal storage disorders, metabolic diseases, and solid tumors.
Gain’s unique approach enables the discovery of novel, allosteric small molecule modulators that can restore or disrupt protein function. Deploying its highly advanced Magellan™ platform, Gain is accelerating drug discovery and unlocking novel disease-modifying treatments for untreatable or difficult-to-treat disorders including neurodegenerative diseases, rare genetic disorders and oncology.
Forward-Looking Statements
This release contains “forward-looking statements” made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements are typically preceded by words such as “believes,” “expects,” “anticipates,” “intends,” “will,” “may,” “should,” or similar expressions. These forward-looking statements reflect management’s current knowledge, assumptions, judgment and expectations regarding future performance or events. Although management believes that the expectations reflected in such statements are reasonable, they give no assurance that such expectations will prove to be correct or that those goals will be achieved, and you should be aware that actual results could differ materially from those contained in the forward-looking statements. Such forward-looking statements include, but are not limited to, statements regarding: the development of the Company’s current or future product candidates including GT-02287 and GT-04686; expectations regarding the completion and timing of results from a Phase 1b clinical study for GT-02287, including any extension studies; expectations regarding the timing of patient enrollment for a Phase 1b clinical study for GT-02287, including any extension studies; the timing of any submissions to the FDA or other regulatory bodies and agencies and the timing of any responses from the FDA or other regulatory bodies and agencies; the timing of the commencement of any Phase 2 clinical studies for GT-02287; and the potential therapeutic and clinical benefits of the Company’s product candidates, including GT-02287 and GT-04686. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the Company’s business in general, please refer to the Company’s Form 10-K for the year ended December 31, 2025, and other filings made with the SEC. All forward-looking statements are expressly qualified in their entirety by this cautionary notice. You are cautioned not to place undue reliance on any forward-looking statements, which speak only as of the date of this release. We have no obligation, and expressly disclaim any obligation, to update, revise or correct any of the forward-looking statements, whether because of new information, future events or otherwise.
Investors:
Gain Therapeutics, Inc.
Apaar Jammu
Director, Investor Relations and Public Relations
ajammu@gaintherapeutics.com
LifeSci Advisors LLC
Chuck Padala
Managing Director
chuck@lifesciadvisors.com
Media:
Russo Partners LLC
Nic Johnson and Elio Ambrosio
nic.johnson@russopartnersllc.com
elio.ambrosio@russopartnersllc.com
(760) 846-9256
